A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.

计划入组 42 人 · 首次发布于 2025 年 12 月 18 日

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

计划入组 80 人 · 首次发布于 2026 年 2 月 18 日

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

计划入组 87 人 · 首次发布于 2026 年 8 月 11 日

HER2 targeted ADC(Araris)

HER2-targeted CAR-T

TARGETED GENETICS CORPORATION

United States

TLA Targeted Immunotherapies AB

Sweden

Targeted Medical Pharma, Inc.

United States

Lantern Pharma's LP-184 Receives FDA Fast Track Designation for Triple-Negative Breast Cancer

INOVIQ's Exosome Therapy Shows Promise in Triple-Negative Breast Cancer

Personalized Vaccine Shows Promise in Triple-Negative Breast Cancer